DLH Reports Fiscal 2024 Fourth Quarter Results

In This Article:

DLH Holdings Corp.
DLH Holdings Corp.

Debt Reduced to Under $155 Million as Company Continues its Technology Transformation

ATLANTA, Dec. 04, 2024 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of science research and development, systems engineering and integration, and digital transformation and cyber security solutions to federal health IT and readiness agencies, today announced financial results for its fiscal fourth quarter and fiscal year ended September 30, 2024.

Recent Highlights

  • Reduced debt to $154.6 million as of September 30, 2024 versus $179.4 million as of September 30, 2023. All mandatory principal amortization payments have been satisfied through fiscal 2025.

  • Amended credit facility to provide flexibility for business transition.

  • Announced new business award of $76 million to deliver C5ISR services to the U.S. Navy.

Fourth Quarter Results

  • Fourth quarter revenue was $96.4 million in fiscal 2024 versus $101.5 million in fiscal 2023, reflecting the impact of small business contract conversions in the Company’s Veterans Affairs ("VA") and Department of Defense ("DOD") portfolios.

  • Earnings were $2.3 million, or $0.16 per diluted share, for the fourth quarter of fiscal 2024 versus $(2.6) million, or $(0.18) per diluted share, for the fourth quarter of fiscal 2023, which included a $7.7 million impairment charge relating to certain long-lived real estate assets which reduced net income.

  • Earnings before interest, taxes, depreciation and amortization ("EBITDA") were $10.7 million for the fourth quarter of fiscal 2024 as compared to $4.4 million for the fourth quarter of fiscal 2023, which was impacted by the aforementioned impairment charge. Adjusted EBITDA for the same periods were $10.7 million and $12.1 million, respectively.

Fiscal Year Results

  • Fiscal year 2024 revenue was $395.9 million compared to revenue of $375.9 million in fiscal year 2023, reflecting the full year contribution of the December 2022 acquisition and growth in the Company’s Health and Human Services portfolio, offset by small business conversions in its DOD and VA portfolios.

  • Earnings for the full year were $7.4 million, or $0.51 per diluted share for fiscal 2024 as compared to earnings of $1.5 million, or $0.10 per diluted share in fiscal 2023. Operating results for the prior year were impacted by the impairment charge.

  • EBITDA was $42.0 million for fiscal 2024 as compared to $32.7 million in fiscal 2023. Adjusted EBITDA for the same periods were $42.0 million and $42.1 million, respectively.

  • Contract backlog was $690.3 million as of September 30, 2024 versus $704.8 million as of September 30, 2023.